Erythrodermic psoriasis is a severe variant of psoriasis characterized by prominent erythema, affecting the entire body surface. Management of erythrodermic psoriasis is difficult, not standardized, and often ineffective. As clinical studies are lacking, reporting of clinical experience with secukinumab may help to gather insight in this field. Here, we describe the case of a 55-year-old man, with a 10-year history of moderate-to-severe plaque psoriasis. He presents a flare of erythroderma involving approximately 90% of his body surface area and a Psoriasis Area and Severity Index score of 42, with an important impact on his quality of life (DLQI score was 20.0; Skindex-29 score was 67.2). The patient presented also alexithymic features. Due to severity of clinical features and poor quality of life, the patient started secukinumab treatment; we observed a striking and rapid response to therapy with an excellent safety profile and a satisfactory compliance. Furthermore, therapy with secukinumab considerably enhanced patient's quality of life. Although further studies are needed to better understand the role of the IL-23/Th17 pathway, secukinumab can be an effective therapeutic option for patients affected by erythrodermic psoriasis.

Galluzzo, M., D'Adamio, S., Campione, E., Mazzilli, S., Bianchi, L., Talamonti, M. (2018). A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab. THE JOURNAL OF DERMATOLOGICAL TREATMENT, 29, 17-20 [10.1080/09546634.2018.1524818].

A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab

Galluzzo, M;Campione, E;Mazzilli, S;Bianchi, L;Talamonti, M
2018-01-01

Abstract

Erythrodermic psoriasis is a severe variant of psoriasis characterized by prominent erythema, affecting the entire body surface. Management of erythrodermic psoriasis is difficult, not standardized, and often ineffective. As clinical studies are lacking, reporting of clinical experience with secukinumab may help to gather insight in this field. Here, we describe the case of a 55-year-old man, with a 10-year history of moderate-to-severe plaque psoriasis. He presents a flare of erythroderma involving approximately 90% of his body surface area and a Psoriasis Area and Severity Index score of 42, with an important impact on his quality of life (DLQI score was 20.0; Skindex-29 score was 67.2). The patient presented also alexithymic features. Due to severity of clinical features and poor quality of life, the patient started secukinumab treatment; we observed a striking and rapid response to therapy with an excellent safety profile and a satisfactory compliance. Furthermore, therapy with secukinumab considerably enhanced patient's quality of life. Although further studies are needed to better understand the role of the IL-23/Th17 pathway, secukinumab can be an effective therapeutic option for patients affected by erythrodermic psoriasis.
2018
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - Malattie Cutanee e Veneree
English
alexithymia; anti-IL17 agents; erythrodermic psoriasis; quality of life; secukinumab
Galluzzo, M., D'Adamio, S., Campione, E., Mazzilli, S., Bianchi, L., Talamonti, M. (2018). A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab. THE JOURNAL OF DERMATOLOGICAL TREATMENT, 29, 17-20 [10.1080/09546634.2018.1524818].
Galluzzo, M; D'Adamio, S; Campione, E; Mazzilli, S; Bianchi, L; Talamonti, M
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
A clinical case of severe disease burden an erythrodermic psoriatic patient treated withsecukinumab.pdf

non disponibili

Licenza: Copyright dell'editore
Dimensione 670 kB
Formato Adobe PDF
670 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/205346
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 9
social impact